In less than two decades, lung cancer has emerged from a "non-treatable" disease with dismal prognosis (1) to a role model for the application of precision medicine and immunotherapy to solid tumors. Reduced smoking and advances in lung cancer screening and treatment have all contributed to a steady decline in lung cancer associated mortality during this time period (2) . However, key factors behind the significant progress in therapy and prognosis have also been the identification of molecular subtypes of this cancer and the development of targeted therapies and immunotherapies (3) . As the understanding of lung cancer has moved from histological-based to molecular-based classifications, the identification of new targets, and particularly biomarkers to select patients who may benefit from targeted therapies, has been crucial (4) . In his keynote presentation, Fred Hirsch, former CEO of the International Association for the Study of Lung Cancer (IASLC), reviewed landmark studies that led to advances in lung cancer therapy, from chemotherapy to precision medicine, and, most recently, immunotherapy. Subgroups of patients with lung cancer can today be treated with several
The level of programmed death-ligand 1 (PD-L1) in tumor cells is regarded as a putative biomarker for response to antibodies that target its interaction with the programmed death 1 (PD-1) receptor on T cells (1) . However, clinical implementation of PD-L1 as a biomarker has been compromised by lack of assay standardization and poor performance, and there is an urgent need for better biomarkers to predict response to immune-based therapy (2) . Robert Anders gave an overview of the current knowledge regarding predictive biomarkers of response to anti-PD-1 treatment and the work in his lab to develop better markers for this purpose. In a landmark proof-ofconcept clinical study of colorectal patients receiving anti-PD-1 treatment, Anders and colleagues showed that patients with mismatch repair-deficient tumors (detected as microsatellite instability) exhibited significantly better response to treatment than patients with mismatch repair-proficient tumors (3) . This result has now been expanded to show the efficacy of PD-1 blockade in patients with mismatch repair-deficient tumors regardless of the cancers' tissue of origin, across 12 different tumor types. In all, microsatellite instability and expression of PD-L1 in the tumor tissue had a positive predictive value of around 50% and a negative predictive value of about 15% for response to treatment (4) . Beyond the tumor cells themselves, other features of the tumor immune microenvironment, including immune infiltration, were found to be important predictors of response to anti-PD-1 blockade. When staining tumor tissue from patients with microsatellite instability for PD-L1, they found that PD-L1 was expressed, but not uniformly across the tumor and not by the tumor cells themselves. PD-L1 was expressed by tumor-associated macrophages at the tumor margin, at the invasive front of the tumor (5, 6) . While PD-L1 alone was insufficient for predicting response of patients with merkel cell carcinoma (MCC), a rare aggressive skin cancer, to anti PD-1 therapy, they found that close proximity of PD-1-positive cells and PD-L1positive cells (within 20 µm) was associated with clinical response (7) . In other tumors, Anders' group is developing lymphocyte mapping strategies, which allow them to analyze the localization of different T cell populations relative to tumor tissue. Early results indicate that some tumors exclude T cells whereas others are infiltrated by T cells. Work is in progress to see how this feature may correlate to patient outcome. Much work is still needed to develop new and better markers, and existing markers must be integrated and analyzed in combination.
Conflict of interest: RA has served at the advisory board or as consultant for BMS, AstraZeneca and Merck. immune cells, was recognized as an immunosuppressive checkpoint mediator (1) . CD39 degrades extracellular adenosine tri-phosphate (ATP) released from dead or decaying cells to adenosine mono-phosphate (AMP), which is then converted to adenosine by CD73. The contribution and cooperation between different tumor immune escape mechanisms in NSCLC remains unknown. Anders Tøndell described a study aimed at investigating the phenotype and expression of markers of immunosuppression on key immune cell subtypes in NSCLC, which used tumor and adjacent healthy lung tissue samples from surgicallyresected NSCLC patients. Immune cells were extracted by combining enzymatic and mechanical disaggregation followed by density gradient centrifugation. Expression of markers of immunosuppression was investigated by flowcytometry. The fractions of CD8 + and CD4 + T cells coexpressing CD39 and PD-1 cells were highly increased in tumor compared to healthy lung tissue (median: 34.6% versus 4.3%, p = 0.0005 on CD8 + T cells and 34.9% versus 10.7%, p = 0.0010 on CD4 + T cells). Tumor tissue also showed increased frequencies of CD39 + PD-1-negative CD8 + and CD4 + T cells compared to healthy lung tissue. PD-1 + CD39-negative CD8 + and CD4 + T cells were significantly increased in tumor, although present in both tumor and healthy lung tissue. Regarding T cells with a regulatory phenotype, the total frequency of FoxP3 + CD4 + regulatory T cells as well as co-expression of CD39 and PD-1 on these cells were significantly elevated in tumor compared to adjacent healthy tissue ( Figure 1 ). Similar to tumor-infiltrating T cell subsets, frequencies of CD39expressing tumor-associated macrophages were more than three-fold increased in tumor compared to lung tissue. This data demonstrated that NSCLC tumor-infiltrating immune cells consistently show elevated expression and coexpression of markers of immune suppression on CD4 + , CD8 + , forkhead box P3 (FoxP3 + ) regulatory T cells and tumor-associated macrophages, indicating signaling pathways for immunosuppression and tumor immune-escape acting simultaneously.
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The authors declare that they have no conflict of interest. Tobacco smoking is the number one cause of lung cancer, however up to 15% of lung cancer cases occur in never smokers and the incidence of lung cancer in never smokers appears to be increasing (1) . Although the epigenetic effects of smoking exposure that may represent predisposition to lung cancer and other diseases have been characterized (2) smoking-independent biomarkers of lung cancer risk remain relatively unexplored. Therese Nøst described an epigenome-wide search within a nested case-control study (131 cases, 129 controls) in a Norwegian prospective cohort of women designed to investigate the role of smoking exposure in disease-related associations (3). They found 25 CpG sites associated with lung cancer risk. Stringent adjustment for smoking exposure using a comprehensive smoking index (CSI) revealed two associated CpG sites, the cg10151248 (PC, CSI-adjusted OR = 0.36 [0.25-0.52] per standard deviation change in methylation) and the cg13482620 (B3GNTL1, CSI-adjusted OR = 0.33 [0.22-0.050]). Importantly, analysis of never smokers only and of an independent cohort of smoking-discordant twins confirmed the independence of these markers from smoking exposure. Gene expression profiles related to the smokingindependent CpG sites showed enriched pathways different from those related to smoking-dependent CpG sites and could possibly reflect immunological changes in blood prior to cancer diagnosis. This study illustrates the potential of blood-derived DNA methylation as a biomarker of lung cancer risk, independent of tobacco exposure and related to distinct biological pathways (the work in this abstract was published subsequently as a full paper in Scientific Reports) (3 Yang updated the group on the status of diagnostic and prognostic biomarkers for malignant mesothelioma (2) and reviewed some of the key mechanisms of asbestos-induced carcinogenesis that may begin to unravel mesothelioma pathogenesis (3) . Cell necrosis induced by asbestos causes the release of a critical factor called High Mobility Group Box 1 protein (HMGB1). This protein functions as the "master switch" that kick-starts a series of inflammatory responses. Over time this leads to malignant transformation of mesothelial cells and mesothelioma development (4) . Mesothelioma cells actively secrete HMGB1 and require it for tumor growth and progression. Therefore, targeting HMGB1 could be a novel therapeutic strategy for mesothelioma (5, 6) . Moreover, mesothelioma patients and asbestos-exposed individuals have significantly higher HMGB1 levels compared to heavy smokers or healthy people. Thus, HMGB1 and its specific isoforms are sensitive and specific biomarkers to detect asbestos exposure and to identify mesothelioma patients (5, 7) . Conflict of interest: HY has grants from NIH, DoD and patents related to HMGB1. Circulating extracellular ribonucleic acids (exRNA) are being pursued as potential liquid biopsy biomarkers for many diseases (1) . However, lack of standardized exRNA isolation methods optimized for biofluids continues to hinder progress towards comprehensive profiling and clinical implementation. Klaas Max, from Thomas Tuschl's Laboratory, described their efforts to develop protocols for automated isolation of exRNA from urine and plasma/ serum to facilitate automated parallel processing of hundreds of clinical samples, followed by characterization of cell-free blood exRNA composition as a reference for biomarker studies (2) . Extracellular ribonucleic acid was isolated from several hundered cell-free biofluid samples (serum, plasma, and urine) of patient cohorts including renal failure, cardiovascular disease, allograft recipients, cancer patients, and normal individuals. Using optimized protocols, they recovered nanogram quantities of exRNA per sample at high purity for direct use in complementary deoxyribonucleic acid (cDNA) library preparation. The exRNA biofluid composition was characterized using barcoded small RNA cDNA library preparation in batches of 24 RNA samples, followed by single-end Illumina HiSeq sequencing yielding up to 150 million reads per batch and lane. Sequence reads were demultiplexed and mapped against a curated human reference transcriptome to obtain miRNA read frequency profiles as well as an abundance of fragments of other RNA classes, such as transfer RNAs (tRNAs), small nuclear RNAs (snRNAs), small conditional RNAs (scRNAs), ribosomal RNAs (rRNAs), messenger RNAs (mRNAs), and long non-coding RNAs (lncRNAs). Sequencing data was used for differential analysis of miRNA abundance, which allowed identification of indicators discriminating disease subcategories and diseaseassociated conditions. Small RNA (sRNA)-derived cDNA library sequencing helped to define normal sRNA variability and revealed organ-specific signatures in certain patient cohorts. Furthermore, a unique exRNA phenotype stable for over a year was observed in one of the volunteers characterized by two-fold total miRNA levels and >20-fold elevated endocrine-cell-specific miRNAs in serum and plasma. "External standardization helped to detect quantitative differences in erythrocyte and platelet-specific miRNA contributions and miRNA concentrations between biofluids" (2 Matched/targeted therapy compared with non-matched therapy showed improved progression-free survival, overall survival and response rates (1) . Landmark analyses demonstrated that patients with one molecular alteration who received targeted therapy and had an objective response had longer progression-free survival compared to those who did not achieve response. An ongoing randomized study, IMPACT2, evaluates molecular profiling and targeted agents in patients with metastatic cancer (2) . Challenges in precision medicine include the large amount of complex data from tumor/cell-free DNA profiling, exome sequencing, proteomics, RNA analysis and immune markers that require accurate bio-informatic analysis and interpretation of the results, careful treatment selection and treatment optimization during monitoring of evolving molecular abnormalities. Cancer immunotherapy in implementation of precision oncology is thought to overcome the complexity of molecular profiling, by initiating an immune response against patients' tumors. The approval of pembrolizumab for solid tumors with microsatellite instability (MSI)-high, and the success of Tcell therapy prompted the development of multiple clinical trials of immunotherapy. Innovative biomarker-driven clinical trials, "N of 1" databases and the use of artificial intelligence hold the promise to expedite precision oncology (3 (1). Beyond detection and enumeration, the characterization of single CTCs can contribute to a better understanding of the metastatic process, improve patient prognostication and treatment monitoring. Characterization of CTCs allows the identification of subpopulations with differential prognostic relevance in BC (2) . Specifically, insulin-like growth factor-1 receptor (IGF1R) expression is commonly observed in CTCs of BC. The IGF1R(+) CTC number decreases significantly in metastatic compared to early disease. IGF1R and epithelial calcium-dependent adhesion (E-cadherin) are co-expressed at the single CTC level, and the transition from early to metastatic BC is associated with a reduction in the expression of both molecules on CTCs. Accordingly, IGF1R(+) CTCs were associated with a favorable outcome in early BC (3) . In metastatic disease the detection of CTCs co-expressing putative cancer stem cell (CSC) and epithelial-to-mesenchymal transition (EMT) markers is associated with aggressive disease characteristics and worse outcome in patients undergoing first-line chemotherapy 4 . Moreover, chemotherapy enriched the CSC/EMT phenotype of CTCs and this was associated with human epidermal growth factor receptor 2 (HER2)-negative status and disease progression. Circulating miRNAs have also attracted significant interest as liquid-based biomarkers. The expression of plasma microRNAs (miR-23b, miR-190, miR-21, miR-200b and miR-200c) involved in tumor dormancy, EMT and metastatic dissemination discriminate between early and metastatic disease stage in BC (5) . Furthermore, their expression holds prognostic significance in patients with metastatic disease treated with first-line chemotherapy. Differential expression of these miRNAs is evident before the initiation of adjuvant therapy between patients with early BC who will experience subsequent disease relapse compared to non-relapsed patients. Moreover, differential expression of miRNAs is also observed among patients with early versus late onset of metastasis years before its clinical detection. The above results support the clinical relevance of CTC characterization and metastasis promoting miRNAs for the prediction of tumor dissemination and the refinement of prognosis of patients with BC. During the last century, the field of cancer diagnostics has experienced several revolutions. In a few decades, cancer diagnosis has evolved from histopathological classification of tumor biopsies to non-invasive, ultrasensitive molecular techniques. Continuing technological improvements are starting to enable the diagnosis of tumors by capturing tumor-derived material present in different liquid biosources, such as blood, urine or saliva, in what is commonly referred to as liquid biopsies. "Classical" liquid biopsies aim to detect the presence of biomarkers, either over-or underexpressed sets of genes, or genetic aberrations such as point mutations or gene fusions, which inform treatment decisions. Given the ease of obtaining liquid biopsies, these biomarkers can be monitored longitudinally over time on the same patient, so the treatment can be more precisely tuned in response to the changing levels of these molecules. Different biosources have been successfully obtained from liquid biopsies, including cell-free DNA and RNA, circulating tumor cells, extracellular vesicles (including exosomes, shed microvesicles and apoptotic bodies) and, more recently, blood platelets (1) . Jordi Berenguer discussed exciting new applications of using blood platelets for early detection of cancer. Platelets are known to act as vacuum cleaners in the blood, ingesting tumor-derived material, which can be detected and analysed. For instance, of echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase (EML4-ALK) fusions can be detected in platelets of lung cancer patients with high precision, and this information is highly valuable to decide whether the patient should be treated with crizotinib (2) . Recent publications on platelet-based cancer diagnostics have resulted in a paradigm change: platelets, which don't have a nucleus, interact with tumors and, in turn, change their splicing patterns, becoming what we call tumor-educated platelets (TEPs). Deep sequencing of platelets and TEPs revealed that their landscape of spliced transcripts reflects the characteristics of the tumor. By the combination of deep sequencing and machine learning-based algorithms to cluster platelet samples in an unsupervised fashion, platelets facilitate pancancer diagnostics, tumor type and grade classification and molecular pathway identification with high accuracy (3) . It is important to note that the algorithms are able to classify tumors according to their genetic aberrations indirectly, that is, not finding the aberration per se, but the reaction of the TEPs. Standard therapy in malignant pleural mesothelioma (MPM) induces only partial response in less than half of the patient and no response in the rest due to the intrinsic chemoresistance. Tumor-derived stem cells are responsible for MPM dissemination and progression, but it is not known wether they play a role in chemoresistance of this tumor. At the moment, there are no specific biomarkers predictive of chemo-response in MPM. Vladan Milosevic discussed a study focused on investigating the mechanisms by which MPM stem cells may engender chemoresistant properties as well as identifying potential biomarkers of chemoresistance. MPM cell lines were generated from biopsies and pleural effusions of MPM patients. The stem cell component was isolated by sorting the SRY-box transcription factor 2, octamer 4, nanog homebox and high aldehyde dehydrogenase (SOX2 + Oct4 + Nanog + ALDH bright ) cells and then confirming their clonogenicity and self-renewal potential. MPM stem cells showed higher resistance to cisplatin and pemetrexed compared to non stem cells. High-throughput polymerase chain reaction (PCR) array was used to examine expression of interleukin genes. Higher expression of a vast number of cytokines, particularly of interleukin 1 beta (IL1β) and interleukin 8 (IL8), was observed in MPM stem cells. Targeted Knock-out of IL1β and IL8 in MPM stem cells using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR associated system (CAS) restored chemosensitivity to cisplatin and pemetrexed. IL1β and IL8 up-regulated ABCB5, a drug efflux transporter, in MPM stem cells. Consistently, elevated levels of these two cytokines were observed in cells derived from patients non-responsive to therapy. This study showed that MPM stem cells are resistant to a broad spectrum of effects of first-line drugs (such as cisplatin and pemetrexed). Knock-out experiments suggested that IL1-β and IL-8 autocrine stimulation induced resistance to cytotoxic effects in MPM stem cells, by upregulating ABCB5. Furthermore, detection of both IL1-β and IL-8 production in patientderived cells could predict therapy response.
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Lung cancer biomarkers: Beyond Genomics
Ana I. Robles 1 National Cancer Institute, Bethesda, MD, USA Widespread implementation of lung cancer screening is creating a need for better clinical management options for patients diagnosed with early stage disease. Up to 30% of surgically treated Stage I lung cancer patients will suffer recurrence within 5 years of diagnosis. Ana Robles described ongoing collaborative efforts to generate comprehensive 'omics' profiles for a large cohort of biospecimens from Stage I lung cancer patients with well-curated epidemiological and clinical data at the Laboratory of Human Carcinogenesis, NCI (Figure 1 ). Included are the profiling of genomic, epigenomic, transcriptomic, and metabolomic landscapes, and, more recently, the microbiome of single patients. These rich datasets are being mined to identify diagnostic and prognostic biomarkers that show evidence for statistically significant risk separation and improved predictive value (1) . Specifically, Homeobox protein A9 (HOXA9) promoter methylation has been identified and validated as a prognostic biomarker for patients with Stage I lung adenocarcinoma (2). Robles and colleagues have now developed and optimized an assay that utilizes Droplet Digital PCR (ddPCR) technology to assess HOXA9 promoter methylation in Formalin-Fixed Paraffin-Embedded (FFPE) tissues routinely generated in the clinic (3) . The group, led by Curt Harris, also recently conducted the first comprehensive characterization of the lung cancer microbiome. Evidence from 16S ribosomal RNA (rRNA) and metagenomics analysis indicated the presence of specific bacterial strains in lung tumors (4) . Ongoing animal studies will evaluate how these bacteria affect the lung immune microenvironment and the rate of tumor development. In addition, Machine Learning strategies are being applied to the integrative analysis of these multi-dimensional datasets. The integrative analysis of 'omics' data may provide insight on the early steps of carcinogenesis and a framework to identify clinically relevant biomarkers and probe their mechanistic association with disease.
Conflict of interest: AR has no conflicts of interest. Overtreatment in prostate cancer (Pca) is a burden for health care economy and for quality of life. Correct diagnosis of early stage Pca is challenging given the limitations of the currently available clinical tools and the biological understanding of Pca. There is an urgent need for a reliable diagnostic tool to identify men whose Pca is likely to be most aggressive and life threatening. Cutting-edge 'omics' technologies (metabolomics, transcriptomics, proteomics and genomics) are moving at a breath-taking pace. These techniques have the potential to stratify disease and individualize cancer care, and are thus, a promising choice to advance diagnostics. Moreover, they become especially powerful if applied directly to human tissue samples in order to capture the complexity that is lost in cell lines and animal models. May-Britt Tessem described an approach to Pca biomarker identification based on metabolomics analyses (MR spectroscopy) on prostate tissues coupled with histopathology, gene expression and immunohistochemistry (1) . Using this approach, they examined concentrations of several potential biomarkers for Pca, including citrate and polyamines (2) . The concentrations of these were significantly decreased in malignant aggressive disease, in patients positive for the transmembrane protease, serine 2 (TMPRSS)ERG gene fusion, and in those carrying a novel Wnt5a signature connected to endothelial mesenchymal transition (EMT), the latter of which is associated with recurrent Pca. Additionally, concentrations of citrate and spermine predicted Pca recurrence. Thus, these biomarkers are highly promising as a tool for clinical treatment decisions. The clear molecular mechanism accounting for low levels of polyamines and citrate in human Pca is being debated and these markers are yet to be validated in the clinic. In part, this may be due to the challenge of tissue heterogeneity and the mix of cell types found in tissue analyses. In the future, a protocol that uses multi-omics and spatial information from a single tissue sample may be needed to explore the clinical relevance of the suggested molecular mechanisms in large patient cohorts (3) . The understanding of such biomarkers can personalize Pca diagnosis and open up new treatment strategies.
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therapeutic efficacy superior to the standard formulation of the drug. However, not all tumor models respond equally well to nanomedicines, and clinical trials with nanomedicines typically fail to show improved efficacy across an unstratified patient group. Tools that can be used to preselect patients for nanomedicines would be valuable. Einar Sulheim investigated whether imaging of the tumor vasculature in xenograft models could be used to predict nanoparticle accumulation and hence serve as a biomarker for the use of nanomedicines (1) . Five different tumor models were grown subcutaneously in athymic mice and imaged with X-ray micro-computed tomography (μCT), diffusion weighted and dynamic contrast enhanced magnetic resonance imaging (MRI), and contrast-enhanced ultrasound (Figure 1 ). Parameters obtained from the in vivo imaging were then evaluated for correlation with the accumulation of 100 nm polystyrene nanoparticles. The tumors were also characterized for density of blood vessels and collagen by microscopy of tumor sections. It was found that nanoparticle accumulation correlated with vascular properties. The blood vessel quality, evaluated through the inflow time in the time-intensity curves from contrastenhanced ultrasound imaging, correlated significantly (p = 0.041) with nanoparticle accumulation. This indicates that chaotic vasculature with shunts and dead ends that give microbubble retention also is more susceptible to nanoparticle accumulation. The vascular density, when quantified by microscopy of lectin-perfused blood vessels also correlated significantly (p = 0.0056) with the accumulation of nanoparticles, but this was not captured by the in vivo imaging, probably due to lack of sensitivity towards the smaller vessels. This study indicates that imaging or measurements of the vasculature in tumors could be a useful alternative to theranostics or companion nanoparticles for stratifying patients for therapy with nanomedicines and that blood vessel architecture, and not only leakiness, could be an important factor for nanoparticle accumulation. Conflict of interest: ES has received grant support from the Norwegian Cancer Society. The Cancer Genome Atlas (TCGA) is a joint project of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). Jean Claude Zenklusen, TCGA Director, gave an overview of the project, the largest-scale cancer genomics project to date, and its lasting impact. Begun in 2006 as a pilot project, TCGA collected, in the following 7 years, more than 11,000 cases across 33 tumor types, and generated a vast, comprehensive data set using a variety of technologies to investigate DNA, RNA and protein to investigate the molecular changes that occur in cancer. Tissue sample collection and data generation were completed in 2013 and 2016, respectively. Integrative cross-platform analyses of TCGA data on individual cancer types have been published for all of the tumor types (https://cancergenome.nih.gov/publications) (1) . The value of the TCGA dataset cannot be overstated (2) . In the last decade, the data and publications have become the standard reference for studies in the tumors characterized by the program. Its richness has enabled researchers to use it as the preliminary dataset to generate new hypothesis to further investigate the role of the genomic alterations found. TCGA has also allowed to define a more meaningful taxonomy of cancer types and subtypes, based not on location but biological characteristics, thus enabling more rational treatment course. Surprisingly, the TCGA data has been used in ways that were not envisioned at the onset of the program, such as the mining of the data to discover new viruses and other microbial agents. However, translation to the clinic of the wealth of information gathered during the project has been modest, mainly for the lack of extensive clinical data and outcomes, but also because we have not been able to truly comprehend the complexity of the biological processes that underlie cancer, focusing mainly on single gene mutations that are a poor reflection of the biological reality.
